XML 10 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2025
Apr. 09, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2025    
Document Transition Report false    
Entity File Number 001-39990    
Registrant Name ELICIO THERAPEUTICS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 11-3430072    
Entity Address, Address Line One 451 D Street, 5th Floor    
Entity Address, City or Town Boston    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02210    
City Area Code 857    
Local Phone Number 209-0050    
Title of 12(b) Security Common Stock, par value $0.01    
Trading Symbol ELTX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 81,800,000
Entity Common Stock, Shares Outstanding   18,704,798  
Central Index Key 0001601485    
Amendment Flag true    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Amendment Description This Amendment No. 1 on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K of Elicio Therapeutics, Inc. (the “Company,” “we,” “our,” “us” or “Elicio”) for the fiscal year ended December 31, 2025, as originally filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026 (the “Original 10-K”). The purpose of this Amendment is to include information required by Part III of the Annual Report on Form 10-K that was intentionally omitted from Part III of the Original 10-K. In addition, this Amendment amends Item 15 of Part IV of the Original 10-K to update the exhibit list and to include new certifications by our principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Except as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the dates described in the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that occurred subsequent to such dates. Accordingly, this Amendment should be read in conjunction with the Company’s filings made with the SEC subsequent to the filing of the Original 10-K, as information in such filings may update or supersede certain information contained in this Amendment. As used in this Amendment, unless otherwise stated or the context otherwise indicates, references to “Elicio,” the “Company,” “we,” “our,” “us” or similar terms refer to Elicio Therapeutics, Inc. and our wholly owned subsidiaries following Elicio’s reverse merger transaction (the “Merger”) with Angion Biomedica Corp. (“Angion”) that was completed on June 1, 2023. Terms used but not defined herein shall have the meaning ascribed to them in the Original 10-K.